AB250
Aligning Medicaid prices with Medicare
Date of Vote: April 25, 2023
Chamber of Origin: HouseAB250 from Nevada's 2023 legislative session aims to align the state's prescription drug prices with those negotiated by Medicare under the federal Inflation Reduction Act. Set to take effect in 2026, the bill ensures that Nevada residents, particularly seniors, benefit from reduced drug costs achieved through federal negotiations. Passed along party lines, AB250 reflects a significant effort to make healthcare more affordable in the state by leveraging federal policy to control prescription drug prices
Turning Point Action’s Position
Voted YEA
270% REPUBLICANS100% DEMOCRATS0% INDEPENDENTS
VOTED NAY
1593.33% REPUBLICANS6.67% DEMOCRATS0% INDEPENDENTS
Search by Party
Voted yea
Angie TaylorState HouseNevada
Session Score:16.67
Brittney MillerState HouseNevada
Session Score:16.67
Cameron MillerState HouseNevada
Session Score:20.83
Cecelia GonzálezState HouseNevada
Session Score:18.18
Clara ThomasState HouseNevada
Session Score:13.04
Daniele Monroe-MorenoState HouseNevada
Session Score:14.29
Voted nay
Alexis HansenState HouseNevada
Session Score:95.83
Bea DuranState HouseNevada
Session Score:25.00
Bert GurrState HouseNevada
Session Score:91.67
Brian HibbettsState HouseNevada
Session Score:91.67
Danielle GallantState HouseNevada
Session Score:91.67
Gregory KoenigState HouseNevada
Session Score:91.67
Not voting
No legislators have been found in this category
Present
No legislators have been found in this category
Abstaining
No legislators have been found in this category
DONATE
Our mission is unachievable without your help. We accept a wide range of donation options to ensure the preservation of this great country!
Donate NowDonate Now